ReviewBritish journal of cancer2011
Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer.
Review in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Neuroinflammatory Mechanisms in Depression: From Biomarkers to Anti-Inflammatory Therapy.Brain sciences · 2026Review
- An integral genomic signature approach for tailored cancer therapy using genome-wide sequencing data.Nature communications · 2022Article
- Article
- The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer.OncoTargets and therapy · 2017Article
- Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers.Yonsei medical journal · 2016Article
- The potential of biomarkers in psychiatry: focus on proteomics.Journal of neural transmission (Vienna, Austria : 1996) · 2015Review
- miR-342-3p targets RAP2B to suppress proliferation and invasion of non-small cell lung cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Decreased HCRP1 expression is associated with poor prognosis in breast cancer patients.International journal of clinical and experimental pathology · 2014Article
- New modalities of cancer treatment for NSCLC: focus on immunotherapy.Cancer management and research · 2014Review
- EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.International journal of medical sciences · 2013Review
- Targeting PI3K in Cancer: Any Good News?Frontiers in oncology · 2013Article
- Primary pulmonary mucoepidermoid carcinoma: an analysis of 21 cases.World journal of surgical oncology · 2012Article
- Potential biomarkers in psychiatry: focus on the cholesterol system.Journal of cellular and molecular medicine · 2012Review
- Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis.Lung Cancer (Auckland, N.Z.) · 2012Article
- Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.Frontiers in oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small-cell lung cancer (NSCLC) remains by far the major cause of cancer-related death in the Western world in both men and women. The majority of patients will be diagnosed with metastatic disease, and chemotherapy doublets remain the cornerstone of treatment for these patients. However, chemotherapy has a minimal impact on long-term survival and prognosis remains poor for these patients. Further improvement in treatment is likely to require incorporation of novel targeted therapies. Among these agents, inhibitors of the epidermal growth factor receptor (EGFR) have demonstrated significant activity in the first-, second- or third-line treatment of NSCLC. The purpose of current paper is to present the evidence for using several proposed molecular biomarkers as a tool for selection of NSCLC patients for anti-EGFR treatment. According to current data, EGFR mutation status appears to be the strongest predictor for the selection of NSCLC patients to first-line treatment with EGFR tyrosine kinase inhibitors vs chemotherapy. Use of other biomarkers remains investigational.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.